Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
Akiko Yamamoto,1 Annabelle A Okada,1 Atsuhiko Sugitani,1,2 Daisuke Kunita,1 Tosho Rii,1 Reiji Yokota1 1Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan; 2Department of Ophthalmology, Kugayama Hospital, Tokyo, Japan Purpose: To describe outcomes of intravitreal ranibizu...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-04-01
|
| Series: | Clinical Ophthalmology |
| Online Access: | http://www.dovepress.com/two-year-outcomes-of-pro-re-nata-ranibizumab-monotherapy-for-exudative-a12822 |
| _version_ | 1818845369781452800 |
|---|---|
| author | Yamamoto A Okada AA Sugitani A Kunita D Rii T Yokota R |
| author_facet | Yamamoto A Okada AA Sugitani A Kunita D Rii T Yokota R |
| author_sort | Yamamoto A |
| collection | DOAJ |
| description | Akiko Yamamoto,1 Annabelle A Okada,1 Atsuhiko Sugitani,1,2 Daisuke Kunita,1 Tosho Rii,1 Reiji Yokota1 1Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan; 2Department of Ophthalmology, Kugayama Hospital, Tokyo, Japan Purpose: To describe outcomes of intravitreal ranibizumab using a pro re nata regimen for treatment-naive exudative age-related macular degeneration (AMD), in Japanese patients over the first 2 years. Methods: Clinical records were retrospectively reviewed of 48 eyes of 48 patients with treatment-naive exudative AMD who underwent intravitreal ranibizumab therapy. After three monthly injections (induction), patients were examined monthly, and subsequent injections were performed as needed (pro re nata) for any residual activity, by fundus biomicroscopy and imaging studies, regardless of severity. Results: Twenty-nine (60%) of the patients were men, and 19 (40%) were women; the mean age was 76.1 years. Of the 48 eyes evaluated, 17 (35%) had findings consistent with polypoidal choroidal vasculopathy, and five (10%) with retinal angiomatous proliferation. A mean of 6.0 ranibizumab injections were given in the first year, 3.5 in the second year, and 9.5 over the 2-year period. The best-corrected visual acuity (logarithm of minimum angle of resolution) improved significantly, from 0.35 at baseline to 0.21 at 12 months (P < 0.01), and remained stable at 0.21 at 24 months (P < 0.01). The mean central macular thickness decreased significantly, from 355.4 µm at baseline to 237.9 µm at 12 months (P < 0.01) and 247.7 µm at 24 months (P < 0.01). Conclusion: Improved visual acuity and decreased central macular thickness were observed and maintained over a 2-year period, in a Japanese population receiving 3 monthly induction injections followed by a pro re nata regimen of ranibizumab for exudative AMD. Keywords: optical coherence tomography, polypoidal choroidal vasculopathy, retinal angiomatous proliferation |
| first_indexed | 2024-12-19T05:28:34Z |
| format | Article |
| id | doaj.art-40997e21825f49e686f2368373da3792 |
| institution | Directory Open Access Journal |
| issn | 1177-5467 1177-5483 |
| language | English |
| last_indexed | 2024-12-19T05:28:34Z |
| publishDate | 2013-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-40997e21825f49e686f2368373da37922022-12-21T20:34:18ZengDove Medical PressClinical Ophthalmology1177-54671177-54832013-04-012013default757763Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patientsYamamoto AOkada AASugitani AKunita DRii TYokota RAkiko Yamamoto,1 Annabelle A Okada,1 Atsuhiko Sugitani,1,2 Daisuke Kunita,1 Tosho Rii,1 Reiji Yokota1 1Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan; 2Department of Ophthalmology, Kugayama Hospital, Tokyo, Japan Purpose: To describe outcomes of intravitreal ranibizumab using a pro re nata regimen for treatment-naive exudative age-related macular degeneration (AMD), in Japanese patients over the first 2 years. Methods: Clinical records were retrospectively reviewed of 48 eyes of 48 patients with treatment-naive exudative AMD who underwent intravitreal ranibizumab therapy. After three monthly injections (induction), patients were examined monthly, and subsequent injections were performed as needed (pro re nata) for any residual activity, by fundus biomicroscopy and imaging studies, regardless of severity. Results: Twenty-nine (60%) of the patients were men, and 19 (40%) were women; the mean age was 76.1 years. Of the 48 eyes evaluated, 17 (35%) had findings consistent with polypoidal choroidal vasculopathy, and five (10%) with retinal angiomatous proliferation. A mean of 6.0 ranibizumab injections were given in the first year, 3.5 in the second year, and 9.5 over the 2-year period. The best-corrected visual acuity (logarithm of minimum angle of resolution) improved significantly, from 0.35 at baseline to 0.21 at 12 months (P < 0.01), and remained stable at 0.21 at 24 months (P < 0.01). The mean central macular thickness decreased significantly, from 355.4 µm at baseline to 237.9 µm at 12 months (P < 0.01) and 247.7 µm at 24 months (P < 0.01). Conclusion: Improved visual acuity and decreased central macular thickness were observed and maintained over a 2-year period, in a Japanese population receiving 3 monthly induction injections followed by a pro re nata regimen of ranibizumab for exudative AMD. Keywords: optical coherence tomography, polypoidal choroidal vasculopathy, retinal angiomatous proliferationhttp://www.dovepress.com/two-year-outcomes-of-pro-re-nata-ranibizumab-monotherapy-for-exudative-a12822 |
| spellingShingle | Yamamoto A Okada AA Sugitani A Kunita D Rii T Yokota R Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients Clinical Ophthalmology |
| title | Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients |
| title_full | Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients |
| title_fullStr | Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients |
| title_full_unstemmed | Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients |
| title_short | Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients |
| title_sort | two year outcomes of pro re nata ranibizumab monotherapy for exudative age related macular degeneration in japanese patients |
| url | http://www.dovepress.com/two-year-outcomes-of-pro-re-nata-ranibizumab-monotherapy-for-exudative-a12822 |
| work_keys_str_mv | AT yamamotoa twoyearoutcomesofprorenataranibizumabmonotherapyforexudativeagerelatedmaculardegenerationinjapanesepatients AT okadaaa twoyearoutcomesofprorenataranibizumabmonotherapyforexudativeagerelatedmaculardegenerationinjapanesepatients AT sugitania twoyearoutcomesofprorenataranibizumabmonotherapyforexudativeagerelatedmaculardegenerationinjapanesepatients AT kunitad twoyearoutcomesofprorenataranibizumabmonotherapyforexudativeagerelatedmaculardegenerationinjapanesepatients AT riit twoyearoutcomesofprorenataranibizumabmonotherapyforexudativeagerelatedmaculardegenerationinjapanesepatients AT yokotar twoyearoutcomesofprorenataranibizumabmonotherapyforexudativeagerelatedmaculardegenerationinjapanesepatients |